Diagnostic value of biochemical markers of bone metabolism in treatment of generalized periodontitis in patients with age-related osteoporosis

O. O. Fastovets, I. V. Masheiko, H. B. Peleshenko
Dnipro Medical Academy of the Ministry of Health of Ukraine, Dnipro, Ukraine

Introduction

The topicality of the problem of periodontal diseases is due to their significant prevalence. The purpose of this work is to study the dynamics of markers of bone metabolism in the process of treatment of generalized periodontitis of the II–III levels of severity with age-related osteoporosis and without osteoporotic changes in the skeleton. The examination and treatment of 104 patients, aged 63–78, equal ratio of men and women, was conducted. Among the selected patients, 49 persons had normal bone mineral density, while the remaining 55 had osteoporotic changes in the bone tissue of involutory genesis. All subjects were assessed for the following indicators: mineral density of jaw bone (BMD), concentration of C-propeptide of Type I Procollagen (CICP) in blood plasma, the activity of tartrate-resistant acid phosphatase (TRAP), bone alkaline phosphatase (BAP), osteocalcin, parathyroid hormone in blood serum, concentration of β-CrossLaps in urine, total calcium and inorganic phosphorus content in blood with calculation of the Ca/P index. It was established that in patients with periodontitis of the II–III degree there was a decrease in the BMD of the alveolar bone in comparison with the control values (P < 0.05), whereas the presence of systemic osteopenia worsened the indices (P < 0.001). The least osteoregenerative activity, which was characterized by the decrease in BAP, TRAP and CICP levels, was registered in patients with generalized periodontitis of the III degree on the background of age-related osteoporosis (P < 0.05). In the patients with generalized periodontitis of the III degree of severity, at the beginning of treatment, a weak negative correlation was found between BMD and TRAP activity (r = –0.292, P < 0.05) and mean strength correlation – with β-CrossLaps in urine (r = –0.348, P < 0.01). The concentration of CICP positively correlated with the mineral density of bone tissue from the third month after the start of treatment (r = 0.312, P < 0.05). As a conclusion, the mineral density of alveolar bone in the process of treatment varies unevenly depending on the severity of generalized periodontitis and the character of osteoporotic changes in the skeleton. The biochemical markers of bone metabolism allow the balance of processes of bone resorption and formation to be determined in order to correct treatment of generalized periodontitis.

Keywords: periodontal diseases; osteopenia; bone mineral density; biomarkers.
influence the metabolism of bone tissue are the levels of calcium, phos-
phorus and hormones, which regulate their metabolism, circulating in
the extracellular fluid (NacT & Cornish, 2008). The most informative
markers of bone metabolism, often used in clinical studies, are
considered to be the tartrate-resistant acid phosphatase (TRAP) of blood
serum and C-terminal Telopeptide of Type-1 Collagen (β-CrossLaps) of
urine, which reflect the activity of resorptive processes. At the same
time, osteocalcin (OC), bone alkaline phosphate (BAP), procollagen
type 1 C-terminal propeptide (CICP) of blood serum are most represen-
tative of the activity of processes of bone formation (Lu et al., 2016;
Garnero, 2017). On the whole, the determination of the dynamics of
concentration of the markers of resorption and formation of bone tissue
in biological fluids is required in order to assess the success of treatment
in effecting remission of the destructive processes in the bone tissue.

Apart from the abovementioned biochemical studies, numerous
nominative apparatus methods of diagnostics have been developed
and broadly introduced into clinical practice. They allow accurate
determination of the mineral density of the bone tissue (Dobrovol-
skaja et al., 2017). Thus, the usage of roentgenological investigation
allows not only study of the structure of bone tissue of the peri-
dontal complex, but also determination of whether the patient is in
the risk group of development of periodontal disease (Gajdarova
et al., 2006; Ignasiak et al., 2016), whereas the data from orthopa-
tomography are a reason for roentgenological densitometry (Naka-
moto et al., 2008).

Finally, considering that systemic osteoporosis is a significant
mechanism which leads to the development and complication of ge-
neralized periodontal disease (Boddu et al., 2016), it is necessary
to prescribe specific pathogenic therapy depending on the character
of the metabolic disorders in the bone tissue (Gorb-Gavr'il'chenko &
Strēčenja, 2013; Aspalli et al., 2014; Mordasov & Ivanjuta, 2016).
As a result of the close relationship between the mineral metabo-
lism and the pattern of systemic osteoporosis, many clinicians re-
commend combined pharmacotherapy using anti-resorptive prepa-
rations, calcium and vitamins (Karakov, 2016). Selecting the opti-
 mum medicamental protocol, monitoring of the efficiency of treat-
ment in dynamics, which includes timely correction, is impossible
without determining and monitoring the structural-functional condi-
tion of the bone tissue (Masheiko, 2017; Roschger et al. 2008).

Therefore, considering everything stated above, the objective of
this study was to determine the dynamics of biochemical markers of
metabolism of bone tissue in the process of treatment of generalized
periodontal disease of II–III degree among patients with age-related
osteoporosis and no osteoporotic changes in the skeleton.

Materials and methods

For realisation of the goal, we conducted an integrated study and
treatment of 104 patients with generalized periodontal disease of II–
III degree, aged between 63–78 years, with an equal number of men
and women. To diagnose periodontal disease, we used the classifica-
tion of M. F. Danilevskij (Danilevskij & Borisenko, 2000).

Among the selected patients, 49 had normal mineral density in the
bone tissue, whereas 55 had osteoporotic changes in bone tissue of
involute genesis. The condition of bone tissue was determined on the
bases of the results of studying the mineral density of the bone tissue
(BMD) using the method of dual-energy X-ray absorptiometry using
the Lunar Prodigy apparatus. Measurements were made in the lumbar
vertebrae (LII-LIV), in the area of femoral neck (Neck), greater tro-
chanter (Troc), and Ward's triangle (Ward). Diagnosing osteoporotic
changes in the skeleton was conducted in accordance with the recom-
mandations of the WHO, criteria T, i.e. in relation to the value of
standard deviation (SD) from the normal parameters of peak bone
mass of healthy individuals of a corresponding age. The SD value
below 1 was considered normal, between 1 and 2.5 SD – osteopenia,
below 2.5 SD – osteoporosis (Siris et al., 2014).

Criteria for excluding patients from the scope of the study were as
follows: the general diseases in the anamnesis, which could influence
the mineral density of bone tissue; usage of medical preparations
which contain mineral components; traumas and inflammatory disea-

ses of the bone-joint system, breach of the treatment protocol.

Prior to the study, the patients gave written approval for being
involved in the study.

The patients were divided as follows: 55 patients with senile
osteoporosis were included in the first main group, group I (12 men
and 15 women, who had generalized periodontal disease of II degree
of severity) and the second main group, group II, which included 10 men
and 18 women with aggressive (III type) disease. The comparison
group was formed similarly to the main group in relation to gender-
age and clinical criteria from people who had normal parameters of
mineral bone density. Therefore, the comparison group I included 14
men and 9 women with periodontal disease of the II type; the com-
parison group II – 16 men and 10 women with periodontal disease of
the III type. Also, as the control, we involved 20 people of the same
age group with an equal number of men and women, with condition-
ally healthy periodontal tissues, who had no diagnosed osteoporotic
changes in the bone tissue.

All patients suffering from generalized periodontal disease recei-
ved complex treatment according to the generally accepted protocol
(Borysenko et al., 2005). Prior to the treatment the patients underwent
a professional hygiene regime of the oral cavity, which consisted of
removing the sediments above and under the gums using the “Piezo-
Master” ultrasonic system and the “Vektor” system. For providing
long term stabilization of the pathological process, the dental treat-
ment included therapeutic, surgical and orthopedic methods, and also
consultations and treatment recommended by an endocrinologist.

In the scope of the presented study, all the observed patients were
monitored using computer tomographic scanning of the jaw bones
(Morita, Japan, 2008) to determine destructive changes in the com-
pacted and trabecular bone, and at the same time determine the parame-
ters of BMD in the following zones: alveolar, middle and apical
horizontal, sepal vertical. Alveolar horizontal was considered a con-
ventional line which lay along the crest of alveolar process; middle
horizontal – line which lay across the central part of interdental sep-
tum; apical horizontal – line which connects the tops of the roots, sepal
vertical – line which divides the alveolar line into equal parts in leng-
ghwise direction. The density of the bone tissue was expressed in
Hounsfield numbers (H).

The conclusions on the activity of the processes of destructive
bone tissue were made according to the level of the resorption mar-
kers. In the blood serum, we determined the activity of tartrate-resis-
tant acid phosphatase (TRAP) (μ/l) using a set of Bone-TRAP (IDS).
The concentration of β-CrossLaps fragments in the urine were deter-
dined using the Serum CrossLaps (Osteometer) test-system.

For standard excretion of β-CrossLaps, we used the second sponta-
aneous morning sample of urine with following normalization of its
centration to the amount of creatinine in the analyzed sample.
The results were converted into ng β-CrossLaps to 1 g of creatinine.

The activity of recovery of the bone tissue was determined accor-
ding to the concentration of procollagen type 1 C-terminal propeptide
(CICP) in the blood serum, which was determined using the method of
immune-enzymic analysis with Metra CIPC ELIA Kit («Quidel Cor-
poration», USA) diagnostic set, bone alkaline phosphate (BAP) in
the blood serum using kinetic colorimetric method (U/l), osteocalcin
with N-MID Osteocalcin ELISA (USA) test set.

In addition, we calculated the parameters of mineral metabolism –
concentration of parathyroid hormone in the blood serum using the
“1-PTH ELISA” (DSL, USA) test-system; the content of total calci-
um in the blood by the colorimetric method with Ortho-CresolPhtha-
lein (Kapitanenko & Dochlin, 1988); the content of total non-organic
phosphorus in the blood by the colorimetric method according to the
reaction with Molybdenum-Vanadium reagent (mmol/l) (Kondrahin,
2004) with following calculation of the Ca/P proportion.

The obtained data were statistically analyzed in Statistica 6.0
(Statsoft Inc., USA) pack using the calculation of the Student’s t-crite-
rium at normal distribution of the data and non-parametric Mann-
Whitney test criterion at not normal distribution. The normal distribu-
tion was calculated using the Shapiro-Wilk test criterion. Differences
Results

As we see from the data provided in Table 1, in each group, the most significant changes in the bone tissue density which occurred as a result of the course of treatment were observed in the septal vertical, and also in the alveolar and middle horizontals, i.e. in the areas directly involved in the pathological process of generalized periodontal disease. At the same time, in the alveolar horizontal, the BMD parameters were higher (P < 0.05), though the dynamics of the changes in the process of treatment were similar to other areas of the jaw bones (P > 0.05). The lowest changes in BMD were observed in the apical horizontal, which is explained by the remoteness of this area from the inflammation source localized in the interalveolar septa (P < 0.001).

Separate mention should be made of the significant dependency of the peculiarities of localization of the destructive process on the BMD parameters among the patients with generalized periodontitis. In patients suffering from generalized periodontitis of the III type with predominant vertical type of destruction of the bone tissue, the BMD parameters in certain areas were reduced to 600 N. The determined reduction of the mineral density was followed by disorders in the bone structure manifested by loss of clarity in the trabecular pattern, which was clearer in the upper part of the septa, enlargement of the intratrabecular cavities; thinning of the trabeculae. The described pattern of the pathological process is related to its localization mostly in the areas of cancellous bone tissue, where the metabolic processes take place very actively. Thus, in the abovementioned observarions, the bone tissue was affected by active resorption, which was manifested in rapid decrease in the BMD parameters.

The greatest decrease in the BMD parameters was observed in the alveolar horizontal among the patients suffering from generalized periodontitis which developed following systemic osteoporotic channel of phosphorus in the blood of patients with generalized periodontitis which developed following systemic osteoporotic channel of phosphorus in the blood of patients with generalized periodontitis. At the same time, in the alveolar horizontal, the BMD parameters of the II group of comparison had practically normalized and were close to the parameters of the control, maintaining at this level throughout the monitoring (P > 0.05). In the II group of comparison, the BMD parameters recovered gradually, which was manifested in clinical-X-ray stabilization of the pathological process in the periodontal tissues, though they did not equalize with the parameters of the control (P > 0.05).

At the same time, mineral density of the bone tissue of the patients with generalized periodontitis of the II type (main group I), despite the treatment, remained practically unchanged, and 3 months after the beginning of the treatment it had increased only by 6.1 ± 1.8% from the initial parameters (P > 0.05). A similar insignificant increase was recorded in the next monitoring period. By contrast, during the treatment, the patients of main group II were observed to have a negative dynamic of the BMD parameters. Therefore, 1 month after the beginning of the treatment, the mineral density of the bone tissue had decreased by 4.2 ± 1.2% on average from the initial parameters, and after 3 months – by 6.5 ± 1.8%, having stabilized and demonstrating an insignificant positive dynamic 6 months after the beginning of the treatment (P > 0.05).

The results of the conducted biochemical studies, presented in Table 2, indicated that the level of total calcium in the blood before the treatment of generalized periodontitis in the comparison groups was within the norm, whereas in the main groups, we recorded a statistically reliable decrease of this indicator compared to the control (P < 0.05). A similar difference was observed during 3 months after the beginning of treatment in main group I. Moreover, in main group II, the normalization of the calcium level in the blood serum was not recorded even 6 months after the beginning of the treatment.

### Table 1

<table>
<thead>
<tr>
<th>Group</th>
<th>Alveolar horizontal</th>
<th>Middle horizontal</th>
<th>Apical horizontal</th>
<th>Septal vertical</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>1244.2 ± 78.6</td>
<td>1397.7 ± 106.1</td>
<td>1324.1 ± 84.3</td>
<td>1276.3 ± 98.4</td>
</tr>
<tr>
<td>Comparison</td>
<td>983.9 ± 103</td>
<td>1131.4 ± 95.3</td>
<td>1296.1 ± 118.1</td>
<td>982.3 ± 102.4</td>
</tr>
<tr>
<td>Main</td>
<td>945.4 ± 78.1</td>
<td>1101.7 ± 100.6</td>
<td>1139.4 ± 144.3</td>
<td>982.7 ± 106.5</td>
</tr>
<tr>
<td>before treatment</td>
<td>958.2 ± 148.3</td>
<td>1145.8 ± 97.3</td>
<td>1032.6 ± 117.4</td>
<td>1002.3 ± 93.4</td>
</tr>
<tr>
<td>after 3 months</td>
<td>967.7 ± 132.6</td>
<td>1159.6 ± 134.6</td>
<td>1150.1 ± 120.9</td>
<td>1020.8 ± 114.7</td>
</tr>
<tr>
<td>after 6 months</td>
<td>1046.1 ± 84.5</td>
<td>1201.0 ± 107.8</td>
<td>1158.3 ± 14.7</td>
<td>1093.7 ± 130.2</td>
</tr>
<tr>
<td>II</td>
<td>844.3 ± 79.6</td>
<td>978.3 ± 135.8</td>
<td>1025.4 ± 115.1</td>
<td>880.4 ± 125.3</td>
</tr>
<tr>
<td>before treatment</td>
<td>812.7 ± 140.9</td>
<td>936.1 ± 123.2</td>
<td>1048.2 ± 105.4</td>
<td>829.4 ± 136.1</td>
</tr>
<tr>
<td>after one month</td>
<td>795.6 ± 151.2</td>
<td>922.8 ± 147.5</td>
<td>1109.6 ± 123.6</td>
<td>826.3 ± 123.7</td>
</tr>
<tr>
<td>after 3 months</td>
<td>887.3 ± 133.8</td>
<td>1020.5 ± 158.1</td>
<td>1143.5 ± 128.7</td>
<td>893.8 ± 133.4</td>
</tr>
</tbody>
</table>

*Note:* – the difference is statistically reliable at P < 0.05, **– P < 0.01, ***– P < 0.001 compared to the parameters of the control.

In the experimental groups, at the beginning of the treatment, the level of phosphorus in the blood of patients with generalized periodontitis of the III type was higher than the control parameters (P < 0.05), indicating the prevalence of the bone resorption over the processes of bone tissue formation, unrelated to the mineral density of the skeleton. However, in comparison group II, we recorded a decrease in the concentration of phosphorus in the blood serum to its normalization already in the 3rd month since the treatment began (P < 0.05). By contrast, in all patients of the main groups the level of blood phosphates remained significantly lower than the parameters of the control throughout the study. Also, the prevailing of bone tissue resorption over the processes of its regeneration was indicated by the Ca/P proportion which was much lower than 1.0. In the patients with generalised periodontitis in the main groups I and II this indicator equaled 0.82 ± 0.08 and 0.63 ± 0.07 respectively (P < 0.05 compared to the control).

As we see in Table 2, the systemic osteoporotic phenomenon among the patients with generalized periodontitis was manifested in increase in the concentration of β-CrossLaps fragments in the urine (P < 0.05). And despite the fact that during the study, the patients of the main groups I and II were observed to exhibit a tendency towards decrease in its secretion, this parameter remained heightened even during the period remote from the beginning of the treatment, which indicates...
The highest level of alkaline phosphatase, which indicates the active processes of collagen synthesis in the bone tissue, was observed among the patients of comparison group I, whereas, the patients of the main groups and comparison group II had lower values of this parameter (P = 0.05). In the patients with generalized periodontitis of the III type, which followed osteoporotic changes in the skeleton, the activity of the bone alkaline phosphatase decreased from the control values by 21.8 ± 4.2% (P < 0.001). The latter, perhaps, was caused by the inhibition of the functional activity of the osteoblasts which accompanied the damage to the large volume of the bone tissue, which occurred among the patients.

At the same time, the level of parathormone in all the experimental groups remained within the normal, though in the main groups, we observed a tendency towards the increase of its level to the upper border of the norm, caused by low level of calcium in the blood. Excessive secretion of parathormone following the hypocalcaemia additionally activates osteoclasts, which justifies the prescription of the calcium preparations and vitamin complexes during treatment of destructive forms of generalized periodontal disease (Leonovala et al., 2013; Hellslein et al., 2011).

It is interesting that the dynamic changes in the level procollagen type 1 C-terminal propeptide (CICP) in the blood plasma, which describes the activity of osteoblasts, was different from the pattern of changes of other parameters of osteoregeneration. The highest CICP level observed in comparison groups I and II indicates that despite that decrease in the mineral density of bone tissue of bones of the jaw and significant prevalence of bone resorption over osteosynthesis in the abovementioned patients, the process of bone tissue recovery is developing at a sufficient level. Also, we should mention that the CICP level in the blood plasma normalized 1–3 months after the beginning of the treatment among the patients of the comparison groups. However, in the patients of the main groups the initial CICP level, which was lower by 22.6 ± 4.0% compared to the control (by 26.0 ± 4.3% for the main group II), normalized only 3–6 months after the treatment (P < 0.05).

The same dynamic was observed for the parameters of bone alkaline phosphatase and osteocalcin (Table 2). However, due to significant variation of its parameters, the determined differences compared to the control were statistically unreliable (P > 0.05). On the whole, the determined difference of the parameters of the bone formation reflects the decrease in the activity of the osteoregeneration processes among the patients with generalized periodontitis, who had osteoporotic changes in the entire skeleton.

After generalization and analysis of the quantitative parameters determined for the experimental groups during different periods of the treatment, we conducted a correlation-regression analysis for determining the most significant relations between the indicators of mineral density of the bone tissue (BMD) and biochemical markers of bone metabolism. For the abovementioned analysis, we selected the parameters which changed the most during the treatment: mineral density of the bone tissue in the alveolar and middle horizontal, concentration of tartrate-resistant acid phosphatase (TRAP), bone alkaline phosphatase, procollagen type 1 C-terminal propeptide (CICP) in the blood and β-Cross.laps fragments in urine. The calculated correlational relations are presented in the Table 3 and 4.

### Table 2
Changes in the biochemical parameters of metabolism of bone tissue in the blood and urine of the patients of the main groups (n = 49) and comparison groups (n = 55) over the treatment process compared to the control (M ± m, n = 20)

<table>
<thead>
<tr>
<th>Group</th>
<th>TRAP, U/l</th>
<th>β-Cross.laps, ng/g creatinine</th>
<th>Osteocalcin, ng/mol</th>
<th>BAP, U/l</th>
<th>CICP, ng/mol</th>
<th>Parathormone, pg/ml</th>
<th>Total blood calcium, mmol/l</th>
<th>Total non-organic phosphorus of blood, mmol/l</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>4.88 ± 0.14</td>
<td>1.02 ± 0.05</td>
<td>16.64 ± 0.43</td>
<td>10.73 ± 0.34</td>
<td>61.82 ± 2.45</td>
<td>47.84 ± 3.27</td>
<td>2.32 ± 0.11</td>
<td>1.91 ± 0.16</td>
</tr>
<tr>
<td>before treatment</td>
<td>5.20 ± 0.16</td>
<td>1.12 ± 0.09</td>
<td>16.45 ± 0.44</td>
<td>11.82 ± 0.43</td>
<td>60.73 ± 2.56</td>
<td>46.78 ± 3.41</td>
<td>2.21 ± 0.12</td>
<td>1.95 ± 0.18</td>
</tr>
<tr>
<td>after 1 month</td>
<td>5.11 ± 0.17</td>
<td>1.09 ± 0.07</td>
<td>18.22 ± 0.48*</td>
<td>11.59 ± 0.33</td>
<td>68.02 ± 2.48</td>
<td>47.12 ± 3.37</td>
<td>2.18 ± 0.14</td>
<td>1.98 ± 0.18</td>
</tr>
<tr>
<td>after 3 months</td>
<td>5.15 ± 0.08</td>
<td>1.04 ± 0.08</td>
<td>17.93 ± 0.57</td>
<td>11.52 ± 0.38</td>
<td>71.09 ± 2.63*</td>
<td>46.84 ± 2.82</td>
<td>2.38 ± 0.11</td>
<td>2.07 ± 0.15</td>
</tr>
<tr>
<td>after 6 months</td>
<td>5.05 ± 0.13</td>
<td>1.06 ± 0.09</td>
<td>18.64 ± 0.65*</td>
<td>11.45 ± 0.34</td>
<td>64.30 ± 2.57</td>
<td>47.51 ± 3.25</td>
<td>2.29 ± 0.13</td>
<td>1.86 ± 0.12</td>
</tr>
<tr>
<td>Comparison II</td>
<td>before treatment</td>
<td>5.68 ± 0.21*</td>
<td>1.22 ± 0.08*</td>
<td>15.31 ± 0.55</td>
<td>9.01 ± 0.50*</td>
<td>51.93 ± 2.89*</td>
<td>48.15 ± 2.92</td>
<td>2.17 ± 0.19</td>
</tr>
<tr>
<td>after 1 month</td>
<td>5.34 ± 0.26</td>
<td>1.14 ± 0.11</td>
<td>16.97 ± 0.45</td>
<td>9.23 ± 0.67</td>
<td>57.42 ± 3.01**</td>
<td>48.02 ± 3.19</td>
<td>2.37 ± 0.14</td>
<td>2.31 ± 0.23</td>
</tr>
<tr>
<td>after 3 months</td>
<td>5.24 ± 0.24</td>
<td>1.12 ± 0.09</td>
<td>19.14 ± 0.62**</td>
<td>9.55 ± 0.51</td>
<td>71.72 ± 2.92*</td>
<td>47.48 ± 3.91</td>
<td>2.41 ± 0.24</td>
<td>2.24 ± 0.19</td>
</tr>
<tr>
<td>after 6 months</td>
<td>5.18 ± 0.17</td>
<td>1.09 ± 0.07</td>
<td>17.87 ± 0.56</td>
<td>9.76 ± 0.46</td>
<td>66.76 ± 2.61</td>
<td>47.12 ± 4.06</td>
<td>2.22 ± 0.14</td>
<td>2.03 ± 0.17</td>
</tr>
<tr>
<td>Main I</td>
<td>before treatment</td>
<td>5.59 ± 0.32*</td>
<td>1.26 ± 0.10*</td>
<td>14.61 ± 0.63*</td>
<td>8.69 ± 0.58**</td>
<td>47.85 ± 3.04***</td>
<td>59.22 ± 3.87*</td>
<td>1.85 ± 0.18**</td>
</tr>
<tr>
<td>after 1 month</td>
<td>5.02 ± 0.30</td>
<td>1.23 ± 0.12</td>
<td>16.31 ± 0.44</td>
<td>9.08 ± 0.56*</td>
<td>53.17 ± 2.58*</td>
<td>56.75 ± 3.09</td>
<td>1.95 ± 0.16</td>
<td>2.14 ± 0.16</td>
</tr>
<tr>
<td>after 3 months</td>
<td>4.74 ± 0.27</td>
<td>1.27 ± 0.11*</td>
<td>15.57 ± 0.56</td>
<td>9.31 ± 0.53*</td>
<td>58.73 ± 2.85*</td>
<td>53.16 ± 2.64</td>
<td>2.09 ± 0.15</td>
<td>1.92 ± 0.14</td>
</tr>
<tr>
<td>after 6 months</td>
<td>4.81 ± 0.24</td>
<td>1.22 ± 0.08*</td>
<td>16.03 ± 0.48</td>
<td>9.42 ± 0.56</td>
<td>59.35 ± 2.63*</td>
<td>53.73 ± 3.03</td>
<td>2.23 ± 0.17</td>
<td>1.85 ± 0.15</td>
</tr>
<tr>
<td>Comparison II</td>
<td>before treatment</td>
<td>5.83 ± 0.28*</td>
<td>1.33 ± 0.10*</td>
<td>13.31 ± 0.59***</td>
<td>8.39 ± 0.52**</td>
<td>45.75 ± 2.93***</td>
<td>61.49 ± 4.42*</td>
<td>1.74 ± 0.21*</td>
</tr>
<tr>
<td>after 1 month</td>
<td>5.73 ± 0.25**</td>
<td>1.28 ± 0.11*</td>
<td>13.65 ± 0.62**</td>
<td>8.58 ± 0.51**</td>
<td>48.23 ± 3.02**</td>
<td>58.61 ± 4.15*</td>
<td>1.79 ± 0.23*</td>
<td>2.30 ± 0.10*</td>
</tr>
<tr>
<td>after 3 months</td>
<td>5.23 ± 0.33</td>
<td>1.30 ± 0.11*</td>
<td>14.15 ± 0.64**</td>
<td>8.80 ± 0.48**</td>
<td>54.37 ± 2.76*</td>
<td>48.03 ± 3.89</td>
<td>1.86 ± 0.21</td>
<td>2.18 ± 0.18</td>
</tr>
<tr>
<td>after 6 months</td>
<td>5.16 ± 0.31</td>
<td>1.25 ± 0.10*</td>
<td>14.88 ± 0.59*</td>
<td>8.97 ± 0.45**</td>
<td>55.11 ± 2.54</td>
<td>47.22 ± 3.95</td>
<td>1.90 ± 0.19</td>
<td>2.16 ± 0.22</td>
</tr>
</tbody>
</table>

Note: * – difference is statistically significant at P < 0.05, ** – P < 0.01, *** – P < 0.001 compared to the parameters of the control.
After the relationships between the mineral density of the jaws in the alveolar horizontal (BMD) and parameters of bone tissue metabolism were calculated, in the main groups and comparison groups, we found a relatively low and average negative relation between this parameter and TRAP concentration in the blood and β-CrossLaps in the urine during the first three months of monitoring (P < 0.05). It is interesting that the further correlation of the above-mentioned parameters had a low level of probability (P > 0.05), which indicates the impact of proinflammatory markers on the destruction of bone tissue, and, therefore, the values of the BMD parameters at the beginning of the treatment. However, during the treatment, the levels of the above-mentioned markers gradually decreased and their impact on the parameters of bone mineral density was reduced (see Table 3).

For both experimental groups, we calculated a low positive correlational relationship between bone mineral density and CICP concentration (see Table 4) among the patients of the main group, we determined a statistically significant average negative relation in the main groups with β-Cross-Laps concentration throughout the monitoring and a low relation with TRAP at the beginning of the treatment (P < 0.05). In comparison group II, a similar pattern was determined until the third month of monitoring.

Perhaps, the presence of the abovementioned relations is due to the fact that bone tissue of the alveolar process in the middle horizontal is not directly involved in the inflammatory process in patients with generalized periodontitis, i.e., its resorption level is less than TRAP-conditioned, therefore following osteoprosis, the bone mineral density depends also on other components of the bone homeostasis. This is proved by the extent of correlation of this parameter, which remained quite high with the β-CrossLaps concentration (P < 0.05).

Table 4 Correlation relations (r) between the parameters of bone mineral density of the lower jaw in the middle horizontal and biochemical parameters of bone tissue metabolism among the patients of experimental groups in the process of treatment (n = 104)

<table>
<thead>
<tr>
<th>Group</th>
<th>TRAP</th>
<th>β-CrossLaps</th>
<th>BAP</th>
<th>CICP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Main</td>
<td>before treatment</td>
<td>-0.217*</td>
<td>-0.242*</td>
<td>0.145</td>
</tr>
<tr>
<td></td>
<td>after 1 month</td>
<td>-0.233</td>
<td>-0.197*</td>
<td>0.242*</td>
</tr>
<tr>
<td></td>
<td>after 3 months</td>
<td>-0.148</td>
<td>-0.236*</td>
<td>-0.173</td>
</tr>
<tr>
<td></td>
<td>after 6 months</td>
<td>-0.167</td>
<td>-0.192</td>
<td>0.215</td>
</tr>
<tr>
<td>Comparison I</td>
<td>before treatment</td>
<td>-0.203*</td>
<td>-0.328*</td>
<td>0.262</td>
</tr>
<tr>
<td></td>
<td>after 1 month</td>
<td>-0.176*</td>
<td>-0.222*</td>
<td>0.125</td>
</tr>
<tr>
<td></td>
<td>after 3 months</td>
<td>-0.144</td>
<td>-0.291*</td>
<td>-0.136</td>
</tr>
<tr>
<td></td>
<td>after 6 months</td>
<td>-0.159</td>
<td>-0.247</td>
<td>0.182</td>
</tr>
<tr>
<td></td>
<td>before treatment</td>
<td>-0.274*</td>
<td>-0.302*</td>
<td>0.153</td>
</tr>
<tr>
<td></td>
<td>after 1 month</td>
<td>-0.240</td>
<td>-0.268*</td>
<td>0.164</td>
</tr>
<tr>
<td></td>
<td>after 3 months</td>
<td>-0.193</td>
<td>-0.227</td>
<td>0.207</td>
</tr>
<tr>
<td></td>
<td>after 6 months</td>
<td>-0.162</td>
<td>-0.245</td>
<td>-0.118</td>
</tr>
<tr>
<td></td>
<td>before treatment</td>
<td>-0.217*</td>
<td>-0.343**</td>
<td>0.151</td>
</tr>
<tr>
<td></td>
<td>after 1 month</td>
<td>-0.182*</td>
<td>-0.322*</td>
<td>0.170</td>
</tr>
<tr>
<td></td>
<td>after 3 months</td>
<td>-0.160</td>
<td>-0.279*</td>
<td>0.193*</td>
</tr>
<tr>
<td></td>
<td>after 6 months</td>
<td>-0.151</td>
<td>-0.258*</td>
<td>-0.174</td>
</tr>
</tbody>
</table>

Note: * – difference was statistically reliable at P < 0.05.

Finally, a low positive correlational relationship between BMD and CICP concentration was determined in the comparison groups from the first month of monitoring, whereas in the main groups this began in the third month (P < 0.05). This allows us to conclude that the CICP is good at reflecting the processes of osteoregeneration and remineralization of bone tissue which was not directly involved in the inflammatory dystrophic process.

Finally, we should summarize the data obtained over the treatment of the patients with generalized periodontitis in the different experimental groups. The highest percentage of stable remissions 6 months after the treatment began was recorded in the Ist main group and the Ist comparison group, i.e., among the patients with generalized periodontitis of the II type, who had osteoporotic changes in the skeleton, or did not have them. The treatment efficiency parameters equaled 74.1 ± 8.4% (20 of 27) respectively for the Ist main group and 78.3 ± 8.6% (18 of 23) for the I comparison group (P > 0.05). Far worse results were observed in the II comparison group (patients with generalized periodontitis of the III type with no systemic involutory osteoporotic changes of bones), where the clinical-X-ray stabilization of the disease was observed only in 33.8 ± 9.8% (14 of 26) of the observations (P < 0.05). In the II main group, i.e. the patients with the periodontitis of the III type, which had developed following systemic osteoporotic disorders in the bone tissue, the stable remission 6 months from the beginning of the treatment was recorded only in 8 of 28 patients (28.6 ± 8.5%, P < 0.05). Therefore, the efficiency of the treatment significantly decreases in patients with advanced development of the inflammatory-dystrophic process in the tissues around the teeth. At the same time, the presence of systemic disorders in the bone metabolism complicates the clinical symptomatic, causes more significant imbalance of the resorption-regeneration processes in the alveolar bone, and, therefore complicates the treatment.

Discussion

Generalized periodontitis should be analyzed as an inflammatory-dystrophic multi-factor process in the tissues around the teeth, the development of which depends both on genetic predisposition and external factors, and also individual peculiarities of the metabolic profile of the patient, and finally, the systemic diseases suffered by this patient (Wu et al., 2015; Tsepov et al., 2016; Souza et al., 2017).

Osteoporosis of involutary genesis is a non-favourable factor which complicates generalised periodontal disease, which, first of all, manifests in decrease of the bone mineral density (BMD), particularly the alveolar process (Bodduru et al., 2016). Considering the fact that the alveolar bone is within the source area of the inflammatory-destructive process initiated by the microbial invasion of the periodontal tissues, rapid progression of the bone resorption develops. Also, bone tissue with decreased mineral density has lower reserve potential for recovery, even after eradication of the main periodontopathogenic factors.

Therefore, it is pretty clear that without determining the causes of systemic disorders in the bone tissue, and also their elimination, it is practically impossible to achieve prolonged remission of generalized periodontitis and eliminate the risk of development of relapse and progression of the pathological process (Mordasov & Ivanjuta, 2016). Thus, it is recommended to supplement the main complex treatment of generalized periodontitis by calcium preparations, mineral complexes, and preparations which normalize metabolic processes, particularly in bone tissue (Hellstein et al., 2011; Leonova et al., 2013). Moreover, in cases of diagnosed osteoporosis of patients with generalized periodontal disease, it is recommended to prescribe antosteoporotic preparations (Gorb-Gavr'il'chenko & Strel'chenja, 2013; Aspall et al., 2014). In our opinion, such an approach is entirely justified. However, treatment of osteoporosis cannot be within the competency of only a periodontist and requires participation of specialists in the field.

Certainly, prescribing antiresorptive preparations, as with monitoring the dynamic of changes in bone tissue as a result of treatment is impossible without determining the parameters of bone mineral density (BMD) and study of biochemical markers of bone metabolism.

As the results of our study indicate, bone mineral density changes in a nonuniform manner depending on the severity of generalized periodontitis and manifestation of osteoporotic changes in bone density. In our opinion, this is caused by the fact that the pattern of processes of destruction and recovery of the bone matrix is determined by...
proinflammatory, osteomodeling and osteoregeneration factors, the proportion of which changes and determines the condition of bone tissue at different stages of treatment.

The results we obtained indicate a close relationship between the treatment results and initial periodontal status of patients, i.e. much worse prognosis of treatment outcome in groups with higher level of disease severity, which is proved by the works by our colleagues (Bodduru et al., 2016; Bernal et al., 2018). On the other hand, we demonstrated that the systemic disorders in bone metabolism, particularly involutory genesis, radically complicate the inflammatory-dystrophic process in the tissues around the teeth, decreasing the efficiency of treatment. Therefore, there is a need to adjust the treatment protocol for the abovementioned patients.

Conclusions

The most diagnostically valuable indicators of the condition of bone tissue of patients with generalized periodontal disease of II–III type of severity following involutory osteoporosis with no systemic changes in mineral bone density are the parameters of bone mineral density of the alveolar bone (BMD), and also the β-CrossLaps level in urine and activity of tartrate-resistant acid phosphatase (TRAP) and bone alkaline phosphatase in the blood serum.

The main representative indicator of the inflammatory-destructive process in periodontal disease is decrease in bone mineral density in the alveolar part of jaw bones. This parameter decreases in patients with II type of severity by 13.4 ± 3.2% compared to the control, and in patients with III type by 20.1 ± 3.5% (P < 0.05). Systemic osteopoenic phenomena cause even greater decrease in this parameter to values which in patients with generalized periodontosis of II type of severity were 24.0 ± 4.1% lower than the control level, and lower by 32.1 ± 4.6% (P < 0.001) in patients with III type.

The lowest osteoregenerative activity occurred at the beginning of treatment of patients with generalized periodontal disease of III type, which followed systemic involutory osteoporosis. Therefore, the activity of bone alkaline phosphatase decreased by 21.8 ± 4.0% compared to the control; tartrate-resistant acid phosphatase (TRAP) – by 20.0 ± 3.9% respectively; concentration of procollagen type 1 C-terminal propptide (CICP) – by 26.0 ± 4.3% (P < 0.05).

The main proinflammatory markers on the BMD parameters gradually decrease in the process of treatment, whereas the positive dynamic of osteogenenerative parameters indicate processes of bone tissue recovery, which is recorded only from the third month of monitoring. The mineral metabolism parameters have only supportive significance for assessing bone metabolism.

The patients suffering from generalized periodontal disease of III type of severity have a low negative relationship between mineral density of the alveolar part of the jaw bones and activity of TRAP in the blood (r = –0.292, P < 0.05) and relationship of average extent with concentration of β-CrossLaps in the urine (r = –0.348, P < 0.01). At the same time, concentration of procollagen type 1 C-terminal propeptide positively correlates with bone mineral density from the third month after the start of the treatment (r = 0.312, P < 0.05).

The diagnostic value of biochemical markers of bone tissue metabolism consists in determining the balance in the processes of resorption and formation, at different stages of generalized periodontal disease, which allows one to correctly select the treatment tactics, prescribe the correct pharmacotherapy and prevent the development of complications.

References


the context of systemic osteoporosis. Meditsinskii Alfavit, 2(9), 12–16 (in Russian).


ractions required for coupling of bone formation and resorption. Sem


